Congress continues to press the US Food and Drug Administration to boost its inspection coverage and capacity and not become dependent on alternative tools.
The House Appropriations Committee approved another increase in funding devoted to inspections for fiscal year 2022 and along with it made clear that in-person foreign inspections are preferable. Language in the